sample

Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world's leading professional organization for physicians, researchers and specialists in the field of oncology.

Major annual event for clinical research and innovation in oncology, the ASCO International Conference is held every year in Chicago. Several tens of thousands of international specialists meet there to present research that aimed at improving treatment standards and patient care.

For the 2022 edition which will take place from June 03 to 07, the Methodology and Quality of Life in Oncology Unit (UMQVC) of the CHU of Besançon is proud to announce that it has carried out the methodology, data management and the statistical analysis from seven presentations (four orals and three posters) selected by the scientific committee.

The four oral presentations will focus on results concerning:

Comparison of the efficacy of two types of therapeutic sequences in patients with metastatic colorectal cancer without KRAS/NRAS/BRAF mutation (Strategic-1 study)1

The benefit of adapted physical activity on the health-related quality of life of patients with metastatic pancreatic cancer (APACAP study)²

Evaluation of the benefit of adding adjuvant chemotherapy to hormonal treatment in elderly patients with localized breast cancer at high risk of recurrence (ASTER 70s study) 3

The value of adding immunotherapy to tri-chemotherapy for the treatment of advanced anal canal cancer (SCARCE study)4


The three posters will relate the results concerning:

The efficacy and safety of a vaccine combined with immunotherapy after induction treatment with tri-chemotherapy in patients with metastatic pancreatic cancer (TEDOPAM study)5

The efficacy and safety of dual immunotherapy with or without chemotherapy in patients with advanced biliary tract cancer after failure of first-line chemotherapy treatment (IMMUNOBIL study)6

Feasibility and efficacy of neoadjuvant chemotherapy in patients with resectable pancreatic cancer (PANACHE01 study)7

This excellent report highlights the dynamism of the UMQVC and the richness of its national and international collaborations in the field of oncology.

1 : Strategic 

Titre : STRATEGIC-1: Multi-Line Therapy Trial in Unresectable Wild-Type KRAS/NRAS/BRAF Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III study

Auteurs: Benoist Chibaudel, Louis-Marie Dourthe, Thierry Andre, Julie Henriques, Vincent Bourgeois, Pierre-Luc Etienne, Jérôme Desrame, Elisabeth Carola, Olivier Dupuis, Nabil Baba-Hamed, Dominique Auby, Christophe Louvet, Emmanuel Maillard, Olivier Romano, Christophe Tournigand, Marie-Line Garcia-Larnicol, Einat Shacham Shmueli, Brian Healey Bird, François Ghiringhelli, Aimery de Gramont

Investigateur principal : Benoist Chibaudel (Hôpital Franco-Britannique – Levallois)

Promoteur : GERCOR

2 : APACAP

Titre : Adapted physical activity (APA) in patients with advanced pancreatic cancer (APACaP): Results from a national prospective randomized GERCOR trial

Auteurs : Cindy Neuzillet, Olivier Bouché, Christophe Tournigand, Benoist Chibaudel, Lucile Bouguion, Leïla Bengrine-Lefevre, Daniel Lopez-Trabada Ataz, May Mabro, Jean-Philippe Metgès, Denis Péré-Vergé, Thierry Conroy, Astrid Lièvre, Morgan Andre, Françoise Desseigne, François Goldwasser, Julie Henriques, Amélie Anota, Pascal Hammel

Investigateur principal : Cindy NEUZILLET (Institut Curie - Site de Saint-Cloud)

Promoteur : GERCOR

3 : GERICO

Titre : Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2- breast cancer and a high genomic grade index: the Unicancer ASTER 70s trial

Auteurs : Etienne Brain, Alessandro Viansone, Emmanuelle Bourbouloux, Olivier Rigal, Jean-Marc Ferrero, Sylvie Kirscher, Djelila Allouache, Véronique d’Hondt, Aude-Marie Savoye, Xavier Durando, François Duhoux, Laurence Venat-Bouvet, Emmanuel Blot, Jean-Luc Canon,  Florence Rollot, Hervé Bonnefoi, Jérôme Lemonnier, Magali Lacroix-Triki, Aurélien Latouche, Franck Bonnetain, Dewi Vernerey, GERICO & UCBG/Unicancer

Investigateur principal: Etienne BRAIN (Institut Curie - Site de Saint-Cloud)

Promoteur :  UNICANCER

4 : SCARCE

Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma (SCCA).

Auteurs : Stefano Kim, François Ghiringhelli, Christelle de la Fouchardière, Eric François, Denis Smith, Emmanuelle Samalin, Daniel Lopez-Trabada Ataz, Aurélia Parzy, Jérôme Desramé, Nabil Baba Hamed, Bruno Buecher, David Tougeron, Oliver Bouché, Benoist Chibaudel, Farid El Hajbi, Marie-Line Garcia-Larnicol, Aurélia MeurisseDewi Vernerey, Simon Pernot, Christophe Borg

Investigateur principal: Stefano KIM (CHU de Besançon)

Promoteur : GERCOR

5 : TEDOPAM

A randomized non-comparative phase II study of maintenance OSE2101 vaccine alone or in combination with nivolumab (nivo), or FOLFIRI after induction with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): first interim results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY

Auteurs : Marc Hilmi, Emmanuel Mitry, Anthony Turpin, Olivier Bouché, Jean-Philippe Metges, François Ghiringhelli, Isabelle Trouilloud, Gaël Roth, Isabelle Baumgaertner, Christophe Borg, Hanifa Ammarguellat, Marielle Guillet, Yves Rinaldi, Thierry Lecomte, Christophe Louvet, Aurélien Lambert, Vincent Hautefeuille, Marie-Line Garcia-Larnicol, Julie Henriques, Cindy Neuzillet;

Investigateur principal: Cindy NEUZILLET (Institut Curie - Site de Saint-Cloud)

Promoteur : GERCOR

6 : Immunobil

Titre : Durvalumab plus tremelimumab immunotherapy in patients with advanced biliary tract carcinoma after failure of platinum-based chemotherapy: interim results of the IMMUNOBIL GERCOR D18-1 PRODIGE-57 study 

Auteurs: M. Delaye, E. Assenat, L. Dahan, J-F. Blanc, D. Tougeron, J-P. Metges, A. Lièvre, A. Turpin, R. Guimbaud, C. de la Fouchardiere, H. Castanie, J. Desrame,  A. Pellat, T. Lecomte, A-L. Bignon, V. Hautefeuille, M-L. Garcia-Larnicol, A. Falcoz, M. Ben Abdelghani, C. Neuzillet

Investigateur principal: Cindy NEUZILLET (Institut Curie - Site de Saint-Cloud)

Promoteur : GERCOR

7 : PANACHE01 :

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial

Auteurs : Lilian Schwarz, Jean-Baptiste Bachet, Aurelia Meurisse, Olivier Bouché, Eric Assenat, Guillaume Piessen, Eric Terrebonne, Jean-Yves Mabrut, Angelique Vienot, Pascal Hammel, Nicolas Regenet, Julien Taieb, Olivier Turrini, Francois Paye, Louise Barbier, Fabienne Portales, Stephanie Truant, Antonio Sa Cunha

Investigateur principal : Llilan Schwarz (CHU de Rouen)

Promoteur : CHU de Rouen

About Dewi VERNEREY


    Dewi Vernerey is a research engineer in epidemiology and biostatistics who received a master’s degree cum laude from Joseph Fourier University (Grenoble, France) with a major in engineering statistics. He defended a PhD in epidemiology and statistics in 2016. His PhD research focused on statistical methodology for risk prediction and prognostic score construction in oncology and kidney transplantation.

2015-2022 © Copyright - UMQVC.org

Website by Pearlweb